Testing: Time to Put Patient Safety First.
作者信息
Baker Sharyn D, Bates Susan E, Brooks Gabriel A, Dahut William L, Diasio Robert B, El-Deiry Wafik S, Evans William E, Figg William D, Hertz Dan L, Hicks J Kevin, Kamath Suneel, Kasi Pashtoon Murtaza, Knepper Todd C, McLeod Howard L, O'Donnell Peter H, Relling Mary V, Rudek Michelle A, Sissung Tristan M, Smith D Max, Sparreboom Alex, Swain Sandra M, Walko Christine M
机构信息
College of Pharmacy, The Ohio State University, Columbus, OH.
Herbert Irving Comprehensive Cancer Center, Columbia University, Irving Medical Center, New York, NY.
出版信息
J Clin Oncol. 2023 May 20;41(15):2701-2705. doi: 10.1200/JCO.22.02364. Epub 2023 Feb 23.
Abstract
摘要
相似文献
1
Testing: Time to Put Patient Safety First.
J Clin Oncol. 2023 May 20;41(15):2701-2705. doi: 10.1200/JCO.22.02364. Epub 2023 Feb 23.
2
Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
Pharmacogenomics. 2016 May;17(7):721-9. doi: 10.2217/pgs-2016-0013. Epub 2016 May 16.
3
Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
Cancer Genomics Proteomics. 2013 Mar-Apr;10(2):89-92.
4
Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Int J Cancer. 2018 Jan 15;142(2):424-430. doi: 10.1002/ijc.31065. Epub 2017 Sep 30.
5
Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping.
Oncologist. 2022 May 6;27(5):e420-e421. doi: 10.1093/oncolo/oyac057.
6
DPYD genotyping panels: Impact of population diversity.
Clin Transl Sci. 2024 Apr;17(4):e13805. doi: 10.1111/cts.13805.
7
Universal Pretreatment Genotyping in Fluoropyrimidine Candidates: Still Controversial but With Clear Instructions for Practitioners, at Last!
JCO Oncol Pract. 2020 Dec;16(12):801-802. doi: 10.1200/OP.20.00903.
8
Implementation of DPYD Genotyping in Admixed American Populations: Brazil as a Model Case.
Clin Pharmacol Ther. 2023 Jul;114(1):23-24. doi: 10.1002/cpt.2921. Epub 2023 May 10.
9
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Eur J Hum Genet. 2020 Apr;28(4):508-517. doi: 10.1038/s41431-019-0540-0. Epub 2019 Nov 19.
10
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.
引用本文的文献
1
Genetic variants and clinical determinants affecting the response to 5-Fluorouracil-based treatment in Chilean patients with advanced colorectal cancer.
Front Oncol. 2025 Jul 25;15:1589724. doi: 10.3389/fonc.2025.1589724. eCollection 2025.
2
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice.
Clin Pharmacol Ther. 2025 May;117(5):1194-1208. doi: 10.1002/cpt.3567. Epub 2025 Jan 31.
3
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.
JAMA Netw Open. 2024 Dec 2;7(12):e2449441. doi: 10.1001/jamanetworkopen.2024.49441.
4
The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation.
Pharmacogenet Genomics. 2025 Jan 1;35(1):1-11. doi: 10.1097/FPC.0000000000000547. Epub 2024 Oct 3.
5
Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis.
BMC Cancer. 2024 Sep 30;24(1):1210. doi: 10.1186/s12885-024-12981-5.
6
Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned.
Clin Pharmacol Ther. 2024 Oct;116(4):914-931. doi: 10.1002/cpt.3402. Epub 2024 Aug 21.
7
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase () Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center.
JCO Precis Oncol. 2024 Jun;8:e2300623. doi: 10.1200/PO.23.00623.
8
Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology.
J Clin Oncol. 2024 Apr 1;42(10):1181-1192. doi: 10.1200/JCO.23.01748. Epub 2024 Feb 22.
9
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.
Br J Cancer. 2024 Mar;130(5):808-818. doi: 10.1038/s41416-023-02517-2. Epub 2024 Jan 15.
10
Risk of Toxicity From Topical 5-Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles.
Clin Pharmacol Ther. 2024 Mar;115(3):452-456. doi: 10.1002/cpt.3131. Epub 2023 Dec 18.
本文引用的文献
1
Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Clin Colorectal Cancer. 2022 Sep;21(3):e189-e195. doi: 10.1016/j.clcc.2022.05.001. Epub 2022 May 11.
2
Survey of US Medical Oncologists' Practices and Beliefs Regarding Testing Before Fluoropyrimidine Chemotherapy.
JCO Oncol Pract. 2022 Jun;18(6):e958-e965. doi: 10.1200/OP.21.00874. Epub 2022 Mar 3.
3
Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation.
BMC Cancer. 2022 Jan 8;22(1):47. doi: 10.1186/s12885-022-09171-6.
4
Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis.
Oncologist. 2021 Dec;26(12):1008-1016. doi: 10.1002/onco.13967. Epub 2021 Sep 29.
5
Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.
Ont Health Technol Assess Ser. 2021 Aug 12;21(14):1-186. eCollection 2021.
6
Detecting DPD deficiency: when perfect is the enemy of good.
Cancer Chemother Pharmacol. 2021 May;87(5):717-719. doi: 10.1007/s00280-021-04241-1. Epub 2021 Mar 9.
7
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.
Pharmacogenomics. 2021 Feb;22(3):145-155. doi: 10.2217/pgs-2020-0154. Epub 2021 Jan 7.
8
5-Fluorouracil Response Prediction and Blood Level-Guided Therapy in Oncology: Existing Evidence Fundamentally Supports Instigation.
Ther Drug Monit. 2020 Oct;42(5):660-664. doi: 10.1097/FTD.0000000000000788.
9
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Int J Cancer. 2019 May 1;144(9):2347-2354. doi: 10.1002/ijc.32022. Epub 2019 Jan 4.
10
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.
Zotero 插件